Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
HPV testing alone as a test of cure after treatment with cervical loop excision:: a retrospective register-based cohort study
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Reproductive biology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Reproductive biology.ORCID iD: 0000-0001-6752-531x
Department of Women’s Health, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Reproductive biology.ORCID iD: 0000-0003-4472-840x
2025 (English)In: Infectious Agents and Cancer, E-ISSN 1750-9378, Vol. 20, no 1, article id 59Article in journal (Refereed) Published
Abstract [en]

Background

Women treated with cervical loop electrosurgical excision procedure require follow-up to detect residual or recurrent HSIL+, defined as high-grade squamous intraepithelial lesions, adenocarcinoma in situ or cervical cancer. Currently, co-testing with cytology and human papillomavirus (HPV) analysis is usually recommended. This study investigates whether HPV testing alone is comparable to co-testing in detecting HSIL + up to three years after treatment. Recurrence rates of HSIL + are also presented, with follow-up extending up to 18 years.

Methods

This retrospective cohort study included all 3,540 women treated with a cervical excision in Uppsala County between 1 January 2005 and 31 December 2019. Women with cancer identified in the cone biopsy were excluded. The main outcome was HSIL + detected within three years of follow-up. Sensitivity, specificity and negative predictive value were calculated for the 1,938 women who had a co-testing result as part of their test of cure. Thus, the analysis for the main outcome could finally be performed on 1,938 out of the total number of 3,540 women. Additionally, long-term data on recurrence and time to HSIL+, along with a separate analysis of results prior to cervical cancer diagnosis, were collected for the whole cohort of 3,399 women.

Results

The sensitivity and negative predictive value for detecting HSIL + were 69% and 97% for HPV alone, and 74% and 98% for co-testing, respectively. These differences were not statistically significant. Specificity was higher for HPV alone than for co-testing. The negative predictive value of HPV testing for excluding cervical cancer (n = 5) within three years was 100%. Recurrence rate of HSIL + in the three-year follow up was 8%, and the total recurrence rate of HSIL + with a mean follow-up of nine years was 10%. Mean time to recurrence was 28 months. None of 19 cervical cancer cases identified in the long-term follow-up had a co-testing result showing negative HPV but positive cytology.

Conclusions

HPV testing alone, as a single test, is comparable to co-testing in detecting HSIL + up to three years after treatment independently of margin status, and demonstrates a higher specificity. Cytology plays a very limited role in the test of cure analysis and could therefore be omitted.

Place, publisher, year, edition, pages
BioMed Central (BMC), 2025. Vol. 20, no 1, article id 59
Keywords [en]
Uterine cervical neoplasms, Papillomavirus infections, Conization, Squamous intraepithelial lesions, Adenocarcinoma in situ, Follow-up studies, Retrospective studies
National Category
Cancer and Oncology Gynaecology, Obstetrics and Reproductive Medicine
Identifiers
URN: urn:nbn:se:uu:diva-566524DOI: 10.1186/s13027-025-00690-yISI: 001558888600001PubMedID: 40866961Scopus ID: 2-s2.0-105014617751OAI: oai:DiVA.org:uu-566524DiVA, id: diva2:1997458
Available from: 2025-09-12 Created: 2025-09-12 Last updated: 2025-09-12Bibliographically approved

Open Access in DiVA

fulltext(1290 kB)320 downloads
File information
File name FULLTEXT01.pdfFile size 1290 kBChecksum SHA-512
06f5634e3f8218a559192204288dd1536ea9adb17be6333f5a2b5bb90f604ce9de5923cb2df96a6e3ea1bf6031b93317dc66ba09de4dd4ff9829221ba95759c7
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Håstad, EmmaAarnio, RiinaOlovsson, Matts

Search in DiVA

By author/editor
Håstad, EmmaAarnio, RiinaOlovsson, Matts
By organisation
Reproductive biology
In the same journal
Infectious Agents and Cancer
Cancer and OncologyGynaecology, Obstetrics and Reproductive Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 320 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 618 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf